Newly published details of a pre-planned, six-month interim analysis of a Phase II trial with Takeda Pharmaceutical Co. Ltd.'s dengue candidate vaccine TAK-003 show the tetravalent product elicited a broad antibody response against all four viral serotypes, regardless of previous infection.
Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.
